Infectious disease transmission during organ and tissue transplantation

Emerging Infectious Diseases

Volumn 18, Issue 8, 2012, Pages

  Greenwald, Melissa A ^a   Kuehnert, Matthew J ^b   Fishman, Jay A ^c,d  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOTRANSPLANTATION; ARTICLE; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; DONOR SELECTION; EPIDEMIOLOGICAL DATA; HUMAN; IMMUNE RESPONSE; INCIDENCE; INFECTION; INFECTION RISK; INFORMATION PROCESSING; PREVALENCE; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SEROPREVALENCE; TRANSPLANTATION; WEST NILE FLAVIVIRUS; COMMUNICABLE DISEASE; DONOR; METHODOLOGY; ORGAN TRANSPLANTATION; STANDARD; TISSUE TRANSPLANTATION;

COMMUNICABLE DISEASES; DONOR SELECTION; HUMANS; ORGAN TRANSPLANTATION; RISK FACTORS; TISSUE DONORS; TISSUE TRANSPLANTATION;

EID: 84864451807     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1808.120277     Document Type: Article

References (31)

1. Food and Drug Administration. Emerging infectious diseases: evaluation to implementation for transfusion and transplantation safety public workshop [cited 2011 Feb 13]. http://www.fda.gov/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/...
2. Ison MG, Hager J, Blumberg E, Burdick J, Carney K, Cutler J, Donor-derived disease transmission events in the United States: data reviewed by the OPTN/UNOS Disease Transmission Advisory Committee. Am J Transplant. 2009;9:1929-35.
3. Fischer SA, Graham MB, Kuehnert MJ, Kotton CN, Srinivasan A, Marty FM, Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med. 2006;354:2235-49.
4. Centers for Disease Control and Prevention. Lymphocytic choriomeningitis virus infection in organ transplant recipients-Massachusetts, Rhode Island, 2005. MMWR Morb Mortal Wkly Rep. 2005;54:537-9.
5. Srinivasan A, Burton EC, Kuehnert MJ, Rupprecht C, Sutker WL, Ksiazek TG, Transmission of rabies virus from an organ donor to four transplant recipients. N Engl J Med. 2005;352:1103-11.
6. Rios M, Daniel S, Dayton AI, Wood O, Hewlett IK, Epstein JS, In vitro evaluation of the protective role of human antibodies to West Nile virus (WNV) produced during natural WNV infection. J Infect Dis. 2008;198:1300-8.
7. Murray K, Walker C, Herrington E, Lewis JA, McCormick J, Beasley DW, Persistent infection with West Nile virus years after initial infection. J Infect Dis. 2010;201:2-4.
8. Kumar D, Drebot MA, Wong SJ, Lim G, Artsob H, Buck P, A seroprevalence study of West Nile virus infection in solid organ transplant recipients. Am J Transplant. 2004;4:1883-8.
9. Iwamoto M, Jernigan DB, Guasch A, Trepka MJ, Blackmore CG, Hellinger WC, Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med. 2003;348:2196-203.
10. Centers for Disease Control and Prevention. West Nile virus infections in organ transplant recipients-New York and Pennsylvania, August-September, 2005. MMWR Morb Mortal Wkly Rep. 2005;54:1021-3.
11. Centers for Disease Control and Prevention. West Nile virus transmission via organ transplantation and blood transfusion-Louisiana, 2008. MMWR Morb Mortal Wkly Rep. 2009;58:1263-7.
12. Fishman JA, Strong DM, Kuehnert MJ. Organ and tissue safety workshop 2007: advances and challenges. Cell Tissue Bank. 2009;10:271-80.
13. Cartwright EJ, Prabhu RM, Zinderman CE, Schobert WE, Jensen B, Noble-Wang J, Transmission of Elizabethkingia meningoseptica (formerly Chryseobacterium meningosepticum) to tissue-allograft recipients: a report of two cases. J Bone Joint Surg Am. 2010;92:1501-6.
14. Eastlund T. Infectious disease transmission through cell, tissue, and organ transplantation: reducing the risk through donor selection. Cell Transplant. 1995;4:455-77.
15. Eastlund T. Bacterial infection transmitted by human tissue allograft transplantation. Cell Tissue Bank. 2006;7:147-66.
16. Kainer MA, Linden JV, Whaley DN, Holmes HT, Jarvis WR, Jernigan DB, Clostridium infections associated with musculoskeletal-tissue allografts. N Engl J Med. 2004;350:2564-71.
17. Lee EH, Ferguson D, Jernigan D, Greenwald M, Cote T, Bos JE, Invasive group-A streptococcal infection in an allograft recipient. A case report. J Bone Joint Surg Am. 2007;89:2044-7.
18. Centers for Disease Control and Prevention. Transmission of hepatitis C virus through transplanted organs and tissue-Kentucky and Massachusetts, 2011. MMWR Morb Mortal Wkly Rep. 2011;60:1697-700.
19. Tugwell BD, Patel PR, Williams IT, Hedberg K, Chai F, Nainan OV, Transmission of hepatitis C virus to several organ and tissue recipients from an antibody-negative donor. Ann Intern Med. 2005;143:648-54.
20. Ison MG, Nalesnik MA. An update on donor-derived disease transmission in organ transplantation. Am J Transplant. 2011;11:1123-30.
21. Centers for Disease Control and Prevention. HIV transmitted from a living organ donor-New York City, 2009. MMWR Morb Mortal Wkly Rep. 2011;60:297-301.
22. Strong DM, Nelson K, Pierce M, Stramer SL. Preventing disease transmission by deceased tissue donors by testing blood for viral nucleic acid. Cell Tissue Bank. 2005;6:255-62.
23. Food and Drug Administration. Guidance for industry: MedWatch form 3500A: mandatory reporting of adverse reactions related to human cells, tissues, and cellular and tissue-based products (HCT/Ps) [cited 2011 Mar 19]. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/ucm153082.htm
24. Khoie T, Zinderman CE, Solomon R, Wise RP, Lee KC, Nether K. Clarification of FDA and The Joint Commission reporting requirements for US tissue recipient adverse reactions. Cell Tissue Bank. 2008;9:67-8.
25. Strong DM, Shinozaki N. Coding and traceability for cells, tissues and organs for transplantation. Cell Tissue Bank. 2010;11:305-23.
26. American Association of Tissue Banks. AATB news release: availability of the donor bank assessment interview form [cited 2012 May 16]. http://archive.constantcontact.com/fs076/1102056357439/archive/1109937312309.html
27. Grossi P, Strong DM. The role of testing in determining suitability of donors and tissues. In: Warwick RM, Fehily D, Brubaker SA, editors. Tissue and cell donation: an essential guide. Boston: Blackwell Publishing, 2009.
28. Humar A, Morris M, Blumberg E, Freeman R, Preiksaitis J, Kiberd B, Nucleic acid testing (NAT) of organ donors: is the 'best' test the right test? A consensus conference report. Am J Transplant. 2010;10:889-99.
29. Ellingson K, Seem D, Nowicki M, Strong DM, Kuehnert MJ; Organ Procurement Organization Nucleic Acid Testing Yield Project Team. Estimated risk of human immunodeficiency virus and hepatitis C virus infection among potential organ donors from 17 organ procurement organizations in the United States. Am J Transplant. 2011;11:1201-8.
30. Zou S, Dodd RY, Stramer SL, Strong DM. Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States. N Engl J Med. 2004;351:751-9.
31. Anderson SA, Yang H, Gallagher LM, O'Callaghan S, Forsheee RA, Busch MP, Quantitative estimate of the risks and benefits of possible alternative blood donor deferral strategies for men who have had sex with men. Transfusion. 2009;49:1102-14.